Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.76 |
| ▸ | FAAH | O00519 | 4/20 | 0.57 |
| ▸ | OTC | P00480 | 1/20 | 0.55 |
| ▸ | CASP2 | P42575 | 1/20 | 0.54 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.52 |
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5946298 | 1.00 | NOD1 (0.76) | NOD1FAAHOTCCASP2DNM1 | |
| SCHEMBL16860689 | 1.00 | NOD1 (0.76) | NOD1FAAHOTCCASP2DNM1 | |
| SCHEMBL16860739 | 1.00 | NOD1 (0.76) | NOD1FAAHOTCCASP2DNM1 | |
| SCHEMBL16860754 | 1.00 | NOD1 (0.76) | NOD1FAAHOTCCASP2DNM1 | |
| SCHEMBL16860725 | 0.98 | NOD1 (0.73) | NOD1FAAHOTCCASP2DNM1 | |
| SCHEMBL16860753 | 0.98 | NOD1 (0.73) | NOD1FAAHOTCCASP2DNM1 | |
| SCHEMBL308741 | 0.95 | NOD1 (0.74) | NOD1FAAHCASP2DNM1DPP7 | |
| SCHEMBL1243678 | 0.95 | NOD1 (0.74) | NOD1FAAHCASP2DNM1DPP7 | |
| SCHEMBL15986104 | 0.95 | NOD1 (0.74) | NOD1FAAHCASP2DNM1DPP7 | |
| SCHEMBL13855547 | 0.95 | NOD1 (0.74) | NOD1FAAHCASP2DNM1DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157509-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA | ARROWHEAD RESEARCH CORPORATION | 2012-06-21 | — | — | US | disclosed |
| US-20120157509-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA | ARROWHEAD RESEARCH CORPORATION | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157509-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA | GALK1, GALE, GALNT6 | NOD1 3643/4885FAAH 4334/4885OTC 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.